Posted by Michael Wonder on 12 Jul 2023
Lupin Announces Health Canada approval of tiotropium bromide inhalation powder for treatment of COPD
11 July 2023 - Lupin announced that on 26 May 2023, its Canada subsidiary, Lupin Pharma Canada received approval from Health Canada to market a generic version of Spiriva (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD), in Canada.
Lupin wishes to clarify that tiotropium bromide inhalation powder is indicated in Canada for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
